Canaccord Genuity analyst Kyle Mikson lowered the price target on Biodesix (NASDAQ: BDSX) to $1.50 (from $2.50) while maintaining a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE